ACADIA Pharmaceuticals Inc (ACAD) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACADIA Pharmaceuticals Inc (ACAD)

ACAD 21.49

-3.7%

3:13 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: mopgcw	5/6/2008 4:05:07 PM
	of 588

Zacks.com Huge Upside for Biotech Acadia Tuesday May 6, 9:15 am ET By Jason Napodano, CFA Acadia Pharmaceuticals Inc. (NasdaqGM: ACAD - News) is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. The company currently has five drug programs in clinical and preclinical development directed at large unmet medical needs and major commercial markets. We are expecting a number of positive catalysts in 2008, including a partnership on pimavanserin for phase III trials in schizophrenia and phase IIb data on ACP-104 also in schizophrenia. We continue to recommend the name and are maintaining our $20 price target. We turned bullish on the name after the positive phase IIb data demonstrating the benefit of pimavanserin as an adjunctive therapy to risperidone for the treatment of schizophrenia. Data from this trial was highly encouraging and we think Acadia is now in a strong position to seek a strategic partner perhaps later in 2008. The shares sold off some over the past few months as management has refused to give a timeline or even comment on when a partnership would be formed. We think this is a wise move, as we can site several other biotech firms that are under heavy selling pressure because they have established a partnership timeline and failed to meet it. Nevertheless, when a partnership does come, it could act as major catalyst to send the shares higher. We continue to see fair value at $20 per share. We arrive at this figure by applying a 25x multiple (the current peer-group average) to our 2012 EPS forecast of $2.31, and discounting to present day by 25%. We think this rate is fair, perhaps even high, given the four internal shots on goal before 2011, and collaborative programs with Allergan (NYSE: AGN - News) moving forward.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next